NovaSight Gains 510(k) Clearance for CureSight

NovaSight received 510(k) clearance from the FDA for its CureSight digital therapy device for treatment of amblyopia, also known as lazy eye.

The eye-tracking system trains users as they watch streamed video content of choice through red-blue treatment glasses. 

CureSight blurs the center of vision of the image that is shown to the strong eye using real-time image processing, which encourages the brain to complete the image's fine details from the lazy eye image and trains the two eyes to work as a team.

The FDA clearance was based on positive results from a clinical trial, which showed the digital therapy was noninferior to using a patch.